{
  "meta": {
    "data_length": 2,
    "message": "Statements retrieved successfully",
    "request_url": "http://api.moalmanac.org/statements?proposition_id=2&agent_id=fda&agent_id=ema",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.029796,
    "timestamp_received": "2026-05-13T16:19:32.080119+00:00Z",
    "timestamp_returned": "2026-05-13T16:19:32.109915+00:00Z",
    "trace_id": "3815de29-16ae-4ae9-8c85-68a75f1dcc44"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-05-07"
  },
  "data": [
    {
      "id": 1058,
      "type": "Statement",
      "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
      "contributions": [
        {
          "id": 13,
          "type": "Contribution",
          "agent": {
            "id": "vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute",
            "last_updated": null,
            "url": null
          },
          "description": "Adding EMA approvals for use to database",
          "date": "2024-10-20"
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema.verzenios",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Verzenios (abemaciclib) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.",
          "urls": [
            "https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios",
            "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-05",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.ema.europa.eu/en/medicines",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Eli Lilly Nederland B.V.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Verzenios",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "abemaciclib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2018-10-29",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-03-12",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "indication": {
        "id": "ind:ema.verzenios:0",
        "indication": "Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",
        "initial_approval_date": "2022-04-01",
        "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/verzenios-h-c-004302-ii-0013-epar-assessment-report-variation_en.pdf",
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
        "raw_biomarkers": null,
        "raw_cancer_type": "Breast cancer",
        "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy",
        "icd10": null,
        "regimen_code": null,
        "reimbursement_category": null,
        "reimbursement_date": null,
        "reimbursement_details": null,
        "date_regular_approval": null,
        "date_accelerated_approval": null,
        "document": {
          "id": "doc:ema.verzenios",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Verzenios (abemaciclib) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.",
          "urls": [
            "https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios",
            "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-05",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.ema.europa.eu/en/medicines",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Eli Lilly Nederland B.V.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Verzenios",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "abemaciclib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2018-10-29",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-03-12",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      },
      "proposition": {
        "id": 2,
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictSensitivityTo",
        "biomarkers": [
          {
            "id": 2,
            "name": "HER2-negative",
            "genes": [],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Protein expression"
              },
              {
                "name": "present",
                "value": true
              },
              {
                "name": "marker",
                "value": "Human epidermal growth factor receptor 2 (HER2)"
              },
              {
                "name": "unit",
                "value": "status"
              },
              {
                "name": "equality",
                "value": "="
              },
              {
                "name": "value",
                "value": "Negative"
              }
            ]
          },
          {
            "id": 1,
            "name": "ER positive",
            "genes": [],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Protein expression"
              },
              {
                "name": "present",
                "value": true
              },
              {
                "name": "marker",
                "value": "Estrogen receptor (ER)"
              },
              {
                "name": "unit",
                "value": "status"
              },
              {
                "name": "equality",
                "value": "="
              },
              {
                "name": "value",
                "value": "Positive"
              }
            ]
          },
          {
            "id": 3,
            "name": "PR positive",
            "genes": [],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Protein expression"
              },
              {
                "name": "present",
                "value": true
              },
              {
                "name": "marker",
                "value": "Progesterone receptor (PR)"
              },
              {
                "name": "unit",
                "value": "status"
              },
              {
                "name": "equality",
                "value": "="
              },
              {
                "name": "value",
                "value": "Positive"
              }
            ]
          }
        ],
        "subjectVariant": {},
        "conditionQualifier": {
          "id": 9,
          "conceptType": "Disease",
          "name": "Invasive Breast Carcinoma",
          "primaryCoding": {
            "id": "oncotree:BRCA",
            "code": "BRCA",
            "name": "Invasive Breast Carcinoma",
            "system": "https://oncotree.mskcc.org",
            "systemVersion": "oncotree_2021_11_02",
            "iris": [
              "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"
            ]
          },
          "mappings": []
        },
        "objectTherapeutic": {
          "id": 0,
          "membership_operator": "AND",
          "therapies": [
            {
              "id": 99,
              "conceptType": "Drug",
              "name": "Abemaciclib",
              "primaryCoding": {
                "id": "ncit:C97660",
                "code": "C97660",
                "name": "Abemaciclib",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:1946825",
                    "code": "1946825",
                    "name": "abemaciclib",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1946825"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:792649",
                    "code": "792649",
                    "name": "abemaciclib",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/792649"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:761851004",
                    "code": "761851004",
                    "name": "Abemaciclib",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=761851004&edition=MAIN/2025-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:42539316",
                    "code": "42539316",
                    "name": "Abemaciclib",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/42539316"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "CDK4/6 inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Targeted therapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            },
            {
              "id": 119,
              "conceptType": "Drug",
              "name": "Tamoxifen",
              "primaryCoding": {
                "id": "ncit:C62078",
                "code": "C62078",
                "name": "Tamoxifen",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62078"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:10324",
                    "code": "10324",
                    "name": "tamoxifen",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=10324"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:1436678",
                    "code": "1436678",
                    "name": "tamoxifen",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1436678"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:373345002",
                    "code": "373345002",
                    "name": "Tamoxifen",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=373345002&edition=MAIN/2025-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:4190066",
                    "code": "4190066",
                    "name": "Tamoxifen",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/4190066"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Estrogen receptor inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Hormone therapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            }
          ]
        }
      }
    },
    {
      "id": 2,
      "type": "Statement",
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
      "contributions": [
        {
          "id": 0,
          "type": "Contribution",
          "agent": {
            "id": "vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute",
            "last_updated": null,
            "url": null
          },
          "description": "Initial access of FDA approvals",
          "date": "2024-10-30"
        }
      ],
      "reportedIn": [
        {
          "id": "doc:fda.verzenio",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Verzenio (abemaciclib) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-07",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Eli and Lily Company.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Verzenio",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "abemaciclib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 208716,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2023-03-03",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "indication": {
        "id": "ind:fda.verzenio:0",
        "indication": "Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",
        "initial_approval_date": "2023-03-03",
        "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
        "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
        "raw_biomarkers": "HR+, HER2-negative",
        "raw_cancer_type": "early breast cancer",
        "raw_therapeutics": "Verzenio (abemaciclib) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor)",
        "icd10": null,
        "regimen_code": null,
        "reimbursement_category": null,
        "reimbursement_date": null,
        "reimbursement_details": null,
        "date_regular_approval": null,
        "date_accelerated_approval": null,
        "document": {
          "id": "doc:fda.verzenio",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Verzenio (abemaciclib) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-07",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Eli and Lily Company.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Verzenio",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "abemaciclib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 208716,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2023-03-03",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      },
      "proposition": {
        "id": 2,
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictSensitivityTo",
        "biomarkers": [
          {
            "id": 2,
            "name": "HER2-negative",
            "genes": [],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Protein expression"
              },
              {
                "name": "present",
                "value": true
              },
              {
                "name": "marker",
                "value": "Human epidermal growth factor receptor 2 (HER2)"
              },
              {
                "name": "unit",
                "value": "status"
              },
              {
                "name": "equality",
                "value": "="
              },
              {
                "name": "value",
                "value": "Negative"
              }
            ]
          },
          {
            "id": 1,
            "name": "ER positive",
            "genes": [],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Protein expression"
              },
              {
                "name": "present",
                "value": true
              },
              {
                "name": "marker",
                "value": "Estrogen receptor (ER)"
              },
              {
                "name": "unit",
                "value": "status"
              },
              {
                "name": "equality",
                "value": "="
              },
              {
                "name": "value",
                "value": "Positive"
              }
            ]
          },
          {
            "id": 3,
            "name": "PR positive",
            "genes": [],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Protein expression"
              },
              {
                "name": "present",
                "value": true
              },
              {
                "name": "marker",
                "value": "Progesterone receptor (PR)"
              },
              {
                "name": "unit",
                "value": "status"
              },
              {
                "name": "equality",
                "value": "="
              },
              {
                "name": "value",
                "value": "Positive"
              }
            ]
          }
        ],
        "subjectVariant": {},
        "conditionQualifier": {
          "id": 9,
          "conceptType": "Disease",
          "name": "Invasive Breast Carcinoma",
          "primaryCoding": {
            "id": "oncotree:BRCA",
            "code": "BRCA",
            "name": "Invasive Breast Carcinoma",
            "system": "https://oncotree.mskcc.org",
            "systemVersion": "oncotree_2021_11_02",
            "iris": [
              "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"
            ]
          },
          "mappings": []
        },
        "objectTherapeutic": {
          "id": 0,
          "membership_operator": "AND",
          "therapies": [
            {
              "id": 99,
              "conceptType": "Drug",
              "name": "Abemaciclib",
              "primaryCoding": {
                "id": "ncit:C97660",
                "code": "C97660",
                "name": "Abemaciclib",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:1946825",
                    "code": "1946825",
                    "name": "abemaciclib",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1946825"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:792649",
                    "code": "792649",
                    "name": "abemaciclib",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/792649"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:761851004",
                    "code": "761851004",
                    "name": "Abemaciclib",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=761851004&edition=MAIN/2025-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:42539316",
                    "code": "42539316",
                    "name": "Abemaciclib",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/42539316"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "CDK4/6 inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Targeted therapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            },
            {
              "id": 119,
              "conceptType": "Drug",
              "name": "Tamoxifen",
              "primaryCoding": {
                "id": "ncit:C62078",
                "code": "C62078",
                "name": "Tamoxifen",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62078"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:10324",
                    "code": "10324",
                    "name": "tamoxifen",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=10324"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:1436678",
                    "code": "1436678",
                    "name": "tamoxifen",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1436678"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:373345002",
                    "code": "373345002",
                    "name": "Tamoxifen",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=373345002&edition=MAIN/2025-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:4190066",
                    "code": "4190066",
                    "name": "Tamoxifen",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/4190066"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Estrogen receptor inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Hormone therapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            }
          ]
        }
      }
    }
  ]
}